3 research outputs found
Case report of a phantom pheochromocytoma
Plasma free metanephrines or urinary fractionated metanephrines are the biochemical tests of choice for the diagnosis of pheochromocytoma as
they have greater sensitivity and specificity than catecholamines for pheochromocytoma detection. This case highlights the preanalytical factors
which can influence metanephrine measurement and cause a false positive result. It describes a patient with a high pre-test probability of pheochromocytoma
due to hypertension and a past medical history of adrenalectomy for a purported pheochromocytoma in her home country. When
biochemical screening revealed grossly elevated urine normetanephrine in the presence of a previously identified right adrenal lesion, there was
high clinical suspicion of a pheochromocytoma. However, functional imaging did not support this view which prompted additional testing with
plasma metanephrines. Results for plasma and urine metanephrines were discordant and preanalytical drug interference was suspected. Patient
medications were reviewed and sulfasalazine, an anti-inflammatory drug was identified as the most likely analytical interferent. Urinary fractionated
metanephrines were re-analysed using liquid chromatography tandem mass spectrometry (LC-MS/MS) and all metanephrines were within their
reference intervals. This case illustrates how method-specific analytical drug interference prompted unnecessary expensive imaging, heightened
patient anxiety and resulted in lengthy investigations for what turned out to be a phantom pheochromocytoma
Octreotide use for rescue of vision in a pregnant patient with acromegaly
Pregnancy in acromegaly is rare and generally safe, but tumour expansion may occur. Managing tumour expansion during pregnancy is complex, due to the potential complications of surgery and side effects of anti-tumoural medication. A 32-year-old woman was diagnosed with acromegaly at 11-week gestation. She had a large macroadenoma invading the suprasellar cistern. She developed bitemporal hemianopia at 20-week gestation. She declined surgery and was commenced on 100 ÎĽg subcutaneous octreotide tds, with normalisation of her visual fields after 2 weeks of therapy. She had a further deterioration in her visual fields at 24-week gestation, which responded to an increase in subcutaneous octreotide to 150 ÎĽg tds. Her vision remained stable for the remainder of the pregnancy. She was diagnosed with
gestational diabetes at 14/40 and was commenced on basal bolus insulin regimen at 22/40 gestation. She otherwise had no obstetric complications. Foetal growth continued along the 50th centile throughout pregnancy. She underwent an elective caesarean section at 34/40, foetal weight was 3.2 kg at birth with an APGAR score of 9. The neonate was examined by an experienced neonatologist and there were no congenital abnormalities identified. She opted not to breastfeed and she is menstruating regularly post-partum. She was commenced on octreotide LAR 40 mg and referred for surgery. At last follow-up, 2 years post-partum, the infant has been developing normally. In conclusion, our case describes a first presentation of acromegaly in pregnancy and rescue of visual field loss with somatostatin analogue therapy